文献速递肿瘤 PET/CT神经核医学

基于单羧酸转运宽松环境的混合[18F]氟代戊酸PET-多参数MRI检测与表征脑转移瘤

A hybrid [18F]fluoropivalate PET-multiparametric MRI to detect and characterise brain tumour metastases based on a permissive environment for monocarboxylate transport.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-02-07

研究纳入12例未治疗和10例立体定向放射外科治疗后的颅内转移病患者,采用[18F]氟代戊酸(FPIA)PET-多参数MRI检测脑转移瘤。所有转移瘤FPIA摄取均高于对侧白质(p=0.0001),未治疗组FPIA-PET体积超出增强MRI体积;SUVmax≥2.0患者总生存期较短(中位4 vs 15个月,p=0.0136),PET-mpMRI分级指标可无创预测总生存期,作者认为需更大规模研究。

要点

  • 所有颅内转移瘤FPIA摄取均高于对侧白质(p=0.0001),不受颅外原发肿瘤类型影响。
  • 未治疗组FPIA-PET体积超出增强MRI体积,而立体定向放射外科治疗后肿瘤未见此现象。
  • SUVmax≥2.0患者总生存期较短(中位4 vs 15个月,p=0.0136),增强MRI对预后无信息。

核心结论

  • 重编程的单羧酸代谢相关FPIA-PET为标注颅内转移病提供新见解,作者认为需更大规模PET-mpMRI研究。

研究设计与样本

  • 研究纳入12例未治疗和10例立体定向放射外科(SRS)治疗后患者(±联合治疗4-8周内),采用混合[18F]氟代戊酸(FPIA)PET-多参数MRI。
  • 试验注册号Clinicaltrials.gov NCT04807582,2021年11月3日回顾性注册。

主要发现

  • 所有颅内转移瘤FPIA摄取均高于对侧白质,与颅外原发肿瘤类型无关(p=0.0001)。
  • 未治疗组FPIA-PET体积超出增强MRI体积,而SRS治疗后肿瘤未见此现象。
  • SUVmax≥2.0患者总生存期较短(中位4 vs 15个月,p=0.0136),增强MRI对预后无信息。
  • PET-mpMRI分级指标可无创预测总生存期。
  • 独立代谢组学分析显示颅内转移瘤分别利用或积累单羧酸和酰基肉碱,为FPIA-PET提供共同表型基础。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者认为需更大规模PET-mpMRI研究。
  • 试验为回顾性注册(2021年11月3日)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The incidence of Intracranial Metastatic Disease (IMD) continues to increase in part due to improvements in systemic therapy resulting in durable control of extra-cranial disease (ECD). Contrast-enhanced Magnetic Resonance Imaging (CE-MRI) is the preferred method for imaging IMD, but has limitations particularly in follow-up surveillance scans to optimise patient care. We investigate a new diagnostic approach of hybrid ([18]F]fluoropivalate (FPIA) Positron Emission Tomography-multiparametric MRI (PET-mpMRI), in 12 treatment-naïve and 10 stereotactic radiosurgery (SRS)-treated patients (± combination therapy within 4-8 weeks). High FPIA uptake was seen in all IMD compared to contralateral white matter, regardless of ECD tumour-of-origin (p = 0.0001) and FPIA-PET volumes extended beyond CE-MRI volumes in treatment-naïve but not SRS-treated tumours. Patients with maximum PET Standardised Uptake Value, (SUVmax) ≥ 2.0 showed particularly short overall-survival (median 4 v 15 months, p = 0.0136), while CE-MRI was uninformative regarding outcome; a PET-mpMRI grade-measure also provided non-invasive prediction of overall-survival, warranting larger studies of PET-mpMRI. Independent metabolomics analyses were consistent with shared adaptation of IMD to utilise or accumulate monocarboxylates and acylcarnitines, respectively, providing a common phenotypic basis to FPIA-PET. Reprogrammed monocarboxylate metabolism-related FPIA-PET provides new insights into annotating IMD, to be expounded in future opportunities for therapy decisions for the growing number of cancer patients with IMD [Trial registration reference: Clinicaltrials.gov NCT04807582; 3rd November 2021, retrospectively registered].

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Islam S, Inglese M, Aravind P, et al. A hybrid [18F]fluoropivalate PET-multiparametric MRI to detect and characterise brain tumour metastases based on a permissive environment for monocarboxylate transport. Eur J Nucl Med Mol Imaging. 2025. PMID: 39915301. doi:10.1007/s00259-025-07118-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。